Thank you very much, Mr. Chair. It's always great to hear Mr. Thériault.
I want to thank the witnesses for being here.
Dr. Lewis, I want to thank you as well for all the work you've done on cancer research. I've read up a bit on you, and it's quite astounding what you've accomplished. Thank you for that.
Mr. Davies, I know there have been significant investments in domestic vaccine production, whether we're talking about the National Research Centre's $170 million, the Novavax partnership project at the University of Saskatchewan, Precision, Medicago, AbCellera or Entos, all the different groups that we've invested in. Maybe you can expand on that, but also talk about the importance of those investments and what they might yield down the road.